Attitudes to chemotherapy in patients with ovarian cancer
Richard T. Penson(Massachusetts General Hospital), Martin Gore(Imperial College London), I. Gibbens, C. Gallagher, Michael V. Seiden(Emergency University), Ursula A. Matulonis(Dana-Farber Cancer Institute), Hee Jun Lee(Massachusetts General Hospital), Keith M. Olson(University of Michigan), Fiona L. Dignan(St Thomas' Hospital)
Cited by 34
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k